Best Stocks To Buy For 2013: Dividend

[ December 27, 2014 | Author: Admin | Views: 97229 | Weather: | Mood: normal]

If this were the Summer Olympics not the Winter Games you might say that the Under Armour brand image was teetering on the balance beam right now. At stake: the brand’s reputation for creating cool, techie duds that are worth the high price tags. That came into question last week when some U.S. speedskating team members blamed Under Armour uniforms for their poor showings. But after a uniform switch followed by the same poor results the consensus from four crisis-management gurus suggests that while any damage to the Under Armour brand remains up in the air, it seems to be making many though not all of the right PR moves. How Under Armour needs to continue to respond: Don’t blame the skaters. The skaters can point all the fingers they want, but it’s critical for Under Armour not to. Instead, the brand must continue its strategy of “refusing to react … Continue reading

[ December 24, 2014 | Author: Admin | Views: 59697 | Weather: | Mood: normal]

This is part of a series of extended profiles of the 2014 Separately Managed Account Managers of the Year. Briefer profiles and an overview of the 10th annual SMA Managers of the Year can be found in Investment Advisor’s July 2014 cover story. Additional reporting and video interviews of the winning managers can be found on our 2014 SMA Managers of the Year home page. The first of two SMA Managers of the Year in this category is Dana Investment Advisors for its Large-Cap Equity portfolio. Duane Roberts, who has managed the strategy since its inception in 1999, modestly said Dana’s process “is designed to give us some consistency to outperform in most market environments,” and outperform it has, only underperforming the S&P 500 in two calendar years. The story behind those two years tells you why the Large-Cap Equity strategy is so successful. “Our process is designed to be … Continue reading

[ December 21, 2014 | Author: Admin | Views: 45591 | Weather: | Mood: normal]

Nokia (NYSE: NOK  ) is notably hanging on to its wide patent portfolio instead of selling it toMicrosoft (NASDAQ: MSFT  ) , opting to license its IP to the software giant instead. To date, the company has primarily used its patents defensively. Nokia’s IP is a valuable asset that it can continue to monetize, and the company could potentially pursue Google (NASDAQ: GOOG  ) Android OEMs aggressively for royalties.If so, that would add yet another layer of costs for Android vendors looking to bring devices to market. Even within Nokia’s existing cross-licensing agreements, the company can effectively eliminate its outgoing royalty payments since it will no longer sell handsets, and keep the incoming royalty checks flowing in. In the following video, Erin Kennedy discusses Nokia’s possible patent strategy with Evan Niu, CFA, and Eric Bleeker, CFA. The tech world has been thrown into chaos as the biggest titans invade one another’s turf. At … Continue reading

[ October 29, 2014 | Author: Admin | Views: 36962 | Weather: | Mood: normal]

DELAFIELD, Wis. (Stockpickr) — Corporate insiders sell their own companies’ stock for a number of reasons. Must Read: Warren Buffett’s Top 10 Dividend Stocks They might need the cash for a big personal purchase such as a new house or yacht, or they might need the cash to fund a charity. Sometimes they sell as part of a planned selling program that they have put in place for diversification purposes, which allows them to sell stock in stages instead of selling all at one price. Other times they sell because they think their stock is overvalued and the risk/reward is no longer attractive. Some even dump their own stock because they have inside knowledge that a competitor is eating their lunch and stealing market share. But insiders usually buy their own shares for one reason: They think the stock is a bargain and has tremendous upside. The key word in … Continue reading

[ October 18, 2014 | Author: Admin | Views: 93174 | Weather: | Mood: normal]

My top idea for conservative, income-oriented investors in the coming year is a closed-end fund that invests in public and privately-held companies doing work in the life sciences arena, writes Nate Pile of Nate’s Notes. The life sciences industry includes stocks in biotechnology, pharmaceuticals, diagnostics, managed healthcare and medical equipment, and healthcare information technology and services. This recommended fundHambrecht & Quist Life Sciences Fund (HQL)was also our top pick last year, and the fund rose 44% in 2013. In addition to rising in value, the fund has a dividend policy of paying out 2% of its net asset value of each quarter. By choosing to take this payout in the form of a dividend reinvestment, rather than cash, investors have done very well for themselves as they’ve watched, both the size of their holdings, and the share price itself, increase as the years have rolled by. To be sure, you … Continue reading